Estrogen receptors and biologic response in rat parathyroid tissue and C cells.

T Naveh-Many, … , N Livni, J Silver

*J Clin Invest.* 1992;90(6):2434-2438. [https://doi.org/10.1172/JCI116134](https://doi.org/10.1172/JCI116134).

The expression of the PTH and calcitonin genes is dramatically decreased by 1,25(OH)2D3 in vivo, and the PTH gene expression is increased by hypocalcemia. We have now studied the effect of estrogens on the expression of these genes in vivo. 17 beta-Estradiol, given to ovariectomized rats, led to a fourfold increase in PTH mRNA and calcitonin mRNA levels. These effects occurred 24 h after single injections of 37-145 nmol estradiol, or after constant infusions of 12 pmol/d for 1 or 2 wk, where there was no effect on serum calcium levels. The estrogen receptor mRNA was demonstrated in the thyroparathyroid tissue by polymerase chain reaction. The estrogen binding was localized to the parathyroid and C cells by immunohistochemistry. Uterus weight was increased by repeated larger doses (73 nmol/d x 7) of estradiol, but not by the small doses (12 pmol/d for 1 or 2 wk) which were effective on the PTH and calcitonin genes, suggesting a sensitive endocrine effect. These results confirm that the parathyroid and C cells are target organs for estrogen, leading to an increased expression of PTH and calcitonin, which by their combined anabolic effect on bone would help prevent osteoporosis.
Estrogen Receptors and Biologic Response in Rat Parathyroid Tissue and C Cells

Tally Naveh-Many, Gideon Almogi, Nelly Livni,* and Justin Silver
Minerva Center in Calcium and Bone Metabolism, Nephrology Services; and *Department of Pathology, Hadassah University Hospital, Jerusalem il-91120, Israel

Abstract

The expression of the PTH and calcitonin genes is dramatically decreased by 1,25(OH)2D3 in vivo, and the PTH gene expression is increased by hypocalcemia. We have now studied the effect of estrogens on the expression of these genes in vivo. 17β-Estradiol, given to ovariectomized rats, led to a fourfold increase in PTH mRNA and calcitonin mRNA levels. These effects occurred 24 h after single injections of 37–145 nmol estradiol, or after constant infusions of 12 pmol/d for 1 or 2 wk, where there was no effect on serum calcium levels. The estrogen receptor mRNA was demonstrated in the thyroparathyroid tissue by polymerase chain reaction. The estrogen binding was localized to the parathyroid and C cells by immunohistochemistry. Uterus weight was increased by repeated larger doses (73 nmol/d × 7) of estradiol, but not by the small doses (12 pmol/d for 1 or 2 wk) which were effective on the PTH and calcitonin genes, suggesting a sensitive endocrine effect. These results confirm that the parathyroid and C cells are target organs for estrogen, leading to an increased expression of PTH and calcitonin, which by their combined anabolic effect on bone would help prevent osteoporosis. (J. Clin. Invest. 1992. 90:2434–2438.) Key words: parathyroid hormone • calcitonin • osteoporosis • calcium • estrogens

Introduction

The expression of the PTH and calcitonin genes are both markedly decreased by 1,25(OH)2D3 both in vivo and in vitro (4–6). The PTH gene’s expression is also regulated by calcium, where the major effect is that of a low calcium increasing PTH mRNA levels in vivo (2, 7). In contrast, calcitonin gene expression is not regulated by calcium in vivo (7). At the level of secretion, calcium is the major regulator for both PTH, and calcitonin, with a low calcium being the secretagogue for PTH, and a high calcium for calcitonin.

The major metabolic bone disease is osteoporosis, and in postmenopausal osteoporosis estrogen replacement therapy is the most effective treatment. However, the mechanism of estrogen effect on bone remains to be fully explained. Part of the effect is in all probability due to a direct effect of estrogens on bone. Osteoblasts have been shown to have estrogen receptors (8, 9), and the addition of estrogens to bone cell lines has been shown to have functional effects (10–12) including the synthesis of growth factors such as transforming growth factor β and insulin-like growth factors I and II (13–15). These findings demonstrate that estrogens act directly on bone. Estrogens might also have an indirect effect on bone by regulating the production of the calcium regulating hormones. In vitro studies have shown that estrogens increase the secretion of PTH from both bovine and human parathyroid tissue, and increase the secretion of calcitonin from a medullary carcinoma cell line (16–19). We have now studied the regulation of PTH and calcitonin gene expression in vivo in the rat, and the presence of the estrogen receptor mRNA and protein in the rat parathyroid and C cells.

Methods

Animals. Female rats of the Hebrew University strain weighing 150–170 g were anesthetized by pentobarbital, and bilateral ovariectomies performed. Other rats had sham operations performed. The rats were maintained on a normal diet for 2 wk when they were then administered various treatments. The rats, four in each group, were given no treatment (sham and ovariectomized), or 17β-estradiol (37–145 nmol/d). The β-estradiol (βE2) was given either as a single injection intraperitoneally (i.p.), as daily injections i.p. for 7 d, or as minipumps for 1 or 2 wk in a much lower dose of 12 pmol/d. The rats were then anesthetized blood samples taken, and the parathyroid tissue excised under pentobarbital anesthesia, snap frozen in liquid nitrogen, and stored at −70°C until extraction. The rat uteri were removed and weighed.

RNA extraction and hybridization. RNA was extracted from rat thyroparathyroid tissue by RNAzol (Biotex, Houston, TX). Between 5 and 10 μg of total RNA were used, consisting of RNA from all the tissues in a single rat’s thyroparathyroid tissue, including parathyroids, C cells, and thyroid follicles. RNA was analyzed by dot blots and Northern blots by hybridization with radiolabeled cDNA probes (2–5 × 104 cpm/μg), autoradiographed; and the films scanned with a densitometer. For each experiment analyzed by dot blot the same amount of total thyroparathyroid tissue RNA was used. The filters were extensively washed and then rehybridized with further probes. The rat PTH cDNA is an 833-bp fragment, the calcitonin probe is an ~900 bp fragment. The filters were also hybridized with control genes, using somatostatin cDNA, actin cDNA, and the 1,25(OH)D3 receptor probes as in our published methodologies (1, 3, 20). In both the dot blots and the Northern blots the sequence of hybridization with different probes was random. For gel blot analysis the same amounts of RNA were run for all samples as quantitated by ethidium bromide staining and by spectrophotometry (OD260/OD280 = 2). Results for dot blots are shown as the mean±SE for four rats.

Polymerase chain reaction (PCR).1 PCR for the estrogen receptor gene in rat thyroparathyroid tissue RNA extracts was performed (21, 22). RNA was reverse transcribed into first strand cDNA using a kit (Amersham Corp., Arlington Heights, IL). PCR amplification of the cDNA was performed in a 50 μl reaction mix containing 2 mM dNTP, 1. Abbreviation used in this paper: PCR, polymerase chain reaction.
5 μl 10× TaqI buffer 100–200 ng each of the upstream and downstream oligonucleotides specific to the rat estrogen receptor 3' end of the gene (23) (synthesized in a DNA synthesizer) and 2.5 μl of TaqI DNA polymerase (Boehringer Mannheim Corp., Indianapolis, IN). The oligonucleotide primers used were 5'-TGACTCTGCAGCAACAGCAT-3', and 5'-GAGTCTCGAGTGGTGGT-3'. The oligonucleotide primers were 311 bp apart. The reaction mixture was covered with mineral oil and subjected to 30 cycles of PCR amplification consisting of 1.5 min at 95°C, 2 min at 93°C, and 1.5 min at 72°C. 10 μl of each PCR reaction were analyzed by electrophoresis in 2% agarose gels, transferred onto a nylon membrane (Hybond N; Amersham Corp.) and hybridized to an estrogen receptor cDNA fragment (23). The size of the radiolabeled amplified DNA fragment was consistent with the distance between the primers.

Immunohistochemistry. Immunohistochemistry for the estrogen receptor was performed on formalin-fixed paraffin-embedded tissues by the method of O'Keane et al. (24). The primary antiserum was rabbit antiestriadiol (Diagnostic Products Corp., Los Angeles, CA), or normal rabbit serum as a negative control, the bridging antibody was biotinylated swine antiserum to rabbit immunoglobulin (DAKOPATTS, Copenhagen, Denmark), followed by avidin-peroxidase complexes (DAKO Quik Staining Kit 40; DAKOPATTS). The staining was developed for 10 min in diaminobenzidine solution or for 25 min in a freshly prepared solution of 3-amino-9-ethyl-carbazol. Then the slides were rinsed in tap water, subsequently counterstained with Moyer hematoxylin, and mounted with Canada balsam or glycerol gelatine. The immunocytochemical assay of estrogen receptor with anti-17β-estradiol antibody has been shown to be an accurate and specific method for the determination of estrogen receptors (24). Immunohistochemistry was performed for calcitonin with a polyclonal antibody (DAKOPATTS).

Results

Ovariectomy led to a small, nonsignificant decrease in PTH and calcitonin mRNA levels (Fig. 1). PTH mRNA and calcitonin mRNA levels were markedly increased by 17β-estradiol (Fig. 1). There was no difference for three control genes studied, namely, actin mRNA (Fig. 1 A) which is derived from the total thyroparathyroid tissue, somatostatin mRNA, which is specific for the C cells in the thyroparathyroid tissue (3), and the 1,25(OH)2D3 receptor mRNA levels, which is present in the parathyroid and C cells, but not in the thyroid follicle cells (20) (not shown). The effect of estrogen on PTH mRNA levels was present 6 h after a 73-nmol dose of 17β-estradiol, but less marked than at 24 h (not shown). At 24 h single doses of 73 nmol and 145 nmol 17β-estradiol led to fourfold increases in mRNA levels for both PTH and calcitonin (Fig. 1). Similar increases in mRNA levels were present after 17β-estradiol was given by osmotic minipump at a dose of 12 pmol/d for 7 or 14 d (Fig. 1). There was no difference in serum calciums among the different groups of rats (results not shown). 17β-Estradiol

Figure 1. Effect of estrogens on PTH mRNA and calcitonin mRNA in rat thyroparathyroid tissue. (A) Agarose gel electrophoresis of RNA (6 μg) from a single rat hybridized for PTH mRNA and actin mRNA. Lanes: 1, ovariectomized; 2, 17β-estradiol; 3, sham. (B) PTH mRNA levels derived from dot blots from sham operated, ovariectomized (OVX), and ovariectomized rats given 17β-estradiol (E). E was given in single doses (×1) of 37, 73, and 145 nmol, or 12 pmol/d as a continuous infusion by minipump for 7 or 14 d. (C) Calcitonin mRNA levels in sham, ovariectomized, and E-treated rats. Results for dot blots are shown as the mean±s.e.m. for four rats. □, Sham; ■, OVX; ●, E, 37 nmol × 1; ●, E, 73 nmol × 1; ●, E, 145 nmol × 1; ■ E minipump, 12 pmol/d × 7; ■ E minipump, 12 pmol/d × 14.
in these doses given to ovariectomized rats does not change serum 1,25-dihydroxyvitamin D₃ levels (25). These results demonstrate that estrogens regulate PTH and calcitonin gene expression in vivo. However, they do not demonstrate whether the estrogen effect was direct on the parathyroid and C cells, or indirect, although one parameter of an indirect effect, serum calcium, did not change with ovariectomy or estrogen treatment.

Estrogen acts on its target organs by binding to a specific estrogen receptor; therefore, to investigate whether thyroparathyroid tissue was a candidate target organ for estrogens, we determined whether the estrogen receptor mRNA was present (23). PCR with estrogen receptor oligonucleotide primers using rat thyroparathyroid tissue RNA extracts showed a 311-bp band specific for the estrogen receptor gene indicating that it is expressed in this tissue (Fig. 2). It was also expressed in the rat liver (not shown), and rat uterus but not in rat spleen (Fig. 2). Negative controls showed that there was no contamination in the PCR (Fig. 2). When PCR was performed on EcoRI restricted rat DNA with the same oligonucleotide primers a band of ~850 bp was demonstrated (not shown), which was larger than the 311-bp band that was predicted from the distance between the primers in the estrogen receptor cDNA sequence. This larger PCR product presumably represents an intron, and confirms that there was no DNA contamination of the PCR reaction.

Figure 3. Immunohistochemistry for the estrogen receptor in female rat thyroparathyroid tissue (A–C), and for calcitonin (D), at magnifications of 100 (A), and 400 (B–D). P, parathyroid; C, C cells; T, thyroid follicles. There was nuclear and cytoplasmic staining in the parathyroid and C cells, but not in the thyroid follicle cells.
The PCR product in the rat thyroparathyroid tissue might have been a product of the thyroid follicles, C cells, and parathyroid cells, and it was therefore necessary to demonstrate that the estrogen receptor was specific to the parathyroid and C cells, particularly because binding studies had not demonstrated an estrogen receptor in parathyroid tissue (26). We did this by immunohistochemistry using a polyclonal antibody to 17β-estradiol, whose staining specifically labels the estrogen receptor (24). In the rat thyroparathyroid tissue the estrogen receptor was found in the rat parathyroid and C cells, but not in the thyroid follicles (Fig. 3), or in spleen (not shown). Estrogen receptor was also present in bovine parathyroid tissue (not shown). As a negative control, normal rabbit serum was used instead of the primary antibody. As a positive control, rat uterus and the human ovary were used, where there was positive nuclear staining for the nuclear receptor. In the case of the human ovary, as expected, there was specific staining only of the granulosa cells (not shown). We also repeated these studies on both bovine parathyroid and rat thyroparathyroid tissue using 3-amino-9-ethyl-carbazol as the final stain instead of diaminobenzidine with identical results (not shown). Testosterone antibody did not stain the parathyroid or C cells. Together with the PCR, these results show that estrogen receptor gene and its protein are expressed in the parathyroid and C cells.

Another parameter of estrogen activity was measured in these rats, namely, uterus weight. The uterotrophic effect of estrogens is a well-characterized biological response to administered estrogens. As expected, ovariectomy leads to a large decrease in uterus weight from a mean of 0.7 g to 0.15 g (Fig. 4). A pharmacological dose of 17β-estradiol (73 nmol) given daily for 7 d increased uterus weight twofold. A much smaller dose (12 pmol/d) given by a constant infusion pump for 2 wk did not affect uterus weight (Fig. 4) despite its potent effect on PTH and calcitonin mRNA levels (Fig. 1). This small physiologically relevant dose successfully separated an estrogen effect on the calcium regulating hormones from that on the uterus.

Discussion

The action of estradiol to increase the expression of the PTH and calcitonin genes, and the presence of the estrogen receptor mRNA and protein in the parathyroid and C cells, as shown in this study, together with the earlier reports of a direct effect of estrogens to increase PTH and calcitonin secretion (16–19) establish that these two organs are target organs for estrogens. This effect of estrogens might be important to the normal physiology of calcium homeostasis, by the action of PTH and calcitonin on their target organs, especially bone. In physiologic concentrations, PTH is anabolic to bone by its effect on osteoblasts, which combined with the effect of calcitonin to decrease osteoclastic bone resorption, would result in stronger bones.

The effect of estrogens in patients with osteoporosis was to increase serum PTH levels (27–29) which was postulated to be secondary to an estrogen induced hypocalcemia (27, 29), whilst the effect on calcitonin levels was variable (30, 31) possibly due to the insensitivity of calcitonin immunoassays (32). Our results, together with the earlier in vitro reports of a direct effect of estrogens on PTH and calcitonin secretion (16–19), indicate that the effect of estrogens to increase PTH and calcitonin levels is a direct effect of estrogens on the parathyroid and C cells, respectively. In addition we have preliminary data with bovine parathyroid cells in primary culture, and a calcitonin producing cell line, that estrogens in vitro increase PTH and calcitonin mRNA levels, respectively (Naveh-Many, T., and J. Silver, unpublished results). In the present study serum PTH and calcitonin levels were not measured. However, to determine the importance of estrogens to their physiology it will be necessary to compare PTH and calcitonin mRNA levels, to their serum concentrations, both after the stress of ovariectomy and estrogen replacement, as well as during the normal estrous cycle.

Ovariectomy produces osteopenia in female rats which can be prevented by estrogen therapy (33, 34), or by the administration of parathyroid hormone (35) or diphosphonates (36), which, like calcitonin, inhibit bone resorption. In studies in osteoporotic patients PTH and calcitonin have been shown to have an anabolic effect on trabecular bone with an increase in vertebral bone density. These studies used PTH alone (37) or PTH with 1,25-dihydroxyvitamin D₃ (38), or pulsatile PTH and sequential calcitonin (39). The present study suggests that estrogens act on bone to prevent osteoporosis not only by a direct action on osteoblasts but also indirectly by its action on the parathyroid gland and the C cells. Osteoblasts have estrogen receptors (8, 9), which are probably central to the effects of estrogen on bone, but it is intriguing that the body might use other mechanisms, such as an effect on PTH and calcitonin, to ensure normal bone strength.

17β-Estradiol given at low doses by minipump for 2 wk increased PTH and calcitonin mRNA levels with no uterotrophic effect as measured by uterus weight, which suggests that it might be possible to develop dose regimes for estrogens or estrogen analogues with an effect on the calcium regulating hormones but not on the female phenotypic organs. However, in the present study uterus weight was measured, and not the expression of uterus specific genes, which might be a more relevant parameter. The clearer understanding of estrogen action will allow the development of treatment strategies of relevance to every postmenopausal woman. This is particularly important, because although postmenopausal estrogen replacement leads to a reduction of ~ 60% in hip fractures (40), it may lead to a 1.3-fold increase in breast cancer (41) and a sixfold increase in uterine cancer (42). There is, therefore, an urgent need for new organ-specific estrogen compounds or dose regimes. The biological model, reported here, might allow the successful separation of estrogen’s calcitrophic effect from
its uterotropic effect, which would be useful for the testing of such estrogen analogues.

Acknowledgments
We thank Miriam Offer for expert technical assistance, S. Green, M. G. Rosenfeld, H. Mayer, and J. W. Pike for clones, and H. Cedar for helpful advice.

This work was supported by grants from the National Institutes of Health (grant DK-38696), and the United States-Israel Binational Science Foundation.

References

T. Naveh-Man, G. Almogi, N. Livni, and J. Silver